Clinical Trials
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Status Notes
Study permanently closed to accrual as of 04/01/2024, noon PST.
Research Committee(s)
Genitourinary Cancer
Activated
04-19-2019
Closed
04-01-2024
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1714
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Status Notes
S1714 will permanently close to accrual on November 15, 2021 at 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1600
A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Status Notes
S1600 study will be permanently closed to accrual, effective 10/20/2023.
Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02-21-2019
Closed
10-20-2023
ClinicalTrials.gov Registry Number
NCT03757949
Closed
Phase
Accrual
1%
SWOG Clinical Trial Number
S1614
Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors
Status Notes
Active 2/21/19
Reactivation, effective 7/1/21
Reactivation, effective 7/1/21
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
02-21-2019
Closed
11-15-2022
ClinicalTrials.gov Registry Number
03887702
Closed
Phase
Accrual
73%
SWOG Clinical Trial Number
S1900A
A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA 1/2 MUTATION STAGE IV NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
S1900A is permanently closed to accrual, effective 2/1/21.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-29-2019
ClinicalTrials.gov Registry Number
NCT03845296
Open
Phase
SWOG Clinical Trial Number
LUNGMAP
A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Status Notes
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Activated
01-28-2019
ClinicalTrials.gov Registry Number
NCT03851445
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1801
A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma.
Status Notes
Permanent Closure: Effective May 5, 2022, at 11:59 p.m. Pacific Time.
Research Committee(s)
Melanoma
Activated
12-06-2018
Closed
05-05-2022
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1815
A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
Status Notes
This study permanently closed to accrual effective 2/15/21.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-03-2018
Closed
02-15-2021
Open
Phase
Accrual
77%
SWOG Clinical Trial Number
S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Status Notes
Activated 9/17/18.
Research Committee(s)
Genitourinary Cancer
Other
Symptom Control and Quality of Life
Activated
09-17-2018
Closed
Phase
Accrual
53%
SWOG Clinical Trial Number
S1706
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Status Notes
Permanently Closed to Accrual 07/01/2024, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
09-12-2018
Closed
07-01-2024
ClinicalTrials.gov Registry Number
NCT03598257
Closed
Phase
Accrual
32%
SWOG Clinical Trial Number
S1701
A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Status Notes
Permanent Closure - Effective 09/29/2022
Research Committee(s)
Lung Cancer
Activated
08-09-2018
Closed
09-29-2022
ClinicalTrials.gov Registry Number
03694002
Closed
Phase
Accrual
96%
SWOG Clinical Trial Number
S1712
A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Status Notes
The study is closed to accrual effective 10/20/2022.
Research Committee(s)
Leukemia
Activated
07-20-2018
ClinicalTrials.gov Registry Number
NCT03654768
Open
Phase
Accrual
88%
SWOG Clinical Trial Number
S1703
Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer
Research Committee(s)
Cancer Care Delivery
Breast Cancer
Activated
07-16-2018
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1702
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
Status Notes
This study is closed to accrual effective 9/30/19 at 11:59p.m. PDT.
Research Committee(s)
Myeloma
Activated
03-08-2018
Closed
09-30-2019
Closed
Phase
Accrual
64%
SWOG Clinical Trial Number
S1400K
A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
Effective on 12/21/18, S1400K will be permanently closed to accrual.
Effective on 10/18/18 at 1:00 pm PST, S1400K will be temporarily closed to accrual.
Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Effective on 10/18/18 at 1:00 pm PST, S1400K will be temporarily closed to accrual.
Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
02-05-2018
Closed
12-21-2018
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
S1612
A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older
Status Notes
This study is temporarily closed to accrual, effective 10/22/18.
Research Committee(s)
Leukemia
Activated
12-22-2017
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1619
A Feasibility Trial of Neoadjuvant Cisplatin - Pemetrexed - Atezolizumab with Adjuvant Maintenance Atezolizumab in Resectable Malignant Pleural Mesothelioma
Status Notes
This study will permanently close to Step 1 accrual effective May 1, 2020 at 11:59 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
11-03-2017
Closed
05-01-2020
ClinicalTrials.gov Registry Number
NCT03228537
Closed
Phase
Accrual
42%
SWOG Clinical Trial Number
S1613
A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification
Status Notes
Step 1 is permanently closed to accrual effective December 31, 2021.
Step 2 is permanently closed to accrual effective March 31, 2022.
Step 2 is permanently closed to accrual effective March 31, 2022.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-09-2017
Closed
12-31-2021
Closed
Phase
Accrual
51%
SWOG Clinical Trial Number
S1400F
A PHASE II STUDY OF MEDI4736 AND TREMELIMUMAB AS THERAPY FOR CHECKPOINT INHIBITOR REFRACTORY SQUAMOUS PATIENTS
Status Notes
Effective March 24, 2020 at 12:00 pm PST, S1400F Cohort 2 (Primary Resistance Cohort) will be permanently closed to accrual. This now closes the entire S1400F study to accrual.
Effective November 6, 2019 at 2:00 pm PST, S1400F Cohort 1 (Acquired Resistance Cohort) will be permanently closed to accrual and Cohort 2 (Primary Resistance Cohort) will reactivate and open to accrual.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Effective November 6, 2019 at 2:00 pm PST, S1400F Cohort 1 (Acquired Resistance Cohort) will be permanently closed to accrual and Cohort 2 (Primary Resistance Cohort) will reactivate and open to accrual.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
10-02-2017
Closed
03-24-2020
ClinicalTrials.gov Registry Number
NCT03373760
Closed
Phase
Accrual
67%
SWOG Clinical Trial Number
S1607
A Phase II Study Of Combining Talimogene laherparepvec (T-VEC) And PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy
Status Notes
This study permanently closed to accrual on 11/1/20.
Research Committee(s)
Melanoma
Activated
10-02-2017
Closed
11-01-2020
ClinicalTrials.gov Registry Number
NCT02965716